The NONO antibody (Catalog: 11058-1-AP) is a rabbit-derived polyclonal antibody developed by Proteintech. It recognizes the NONO protein across multiple species, including humans, mice, rats, and zebrafish . Key characteristics include:
Flavivirus Replication: NONO binds to the replication complexes of flaviviruses (e.g., Zika, Japanese encephalitis) via interactions with viral NS3 protein and 3' UTR RNA. It facilitates positive-strand RNA synthesis, critical for viral proliferation .
NONO acts as an oncogenic scaffold in cancers such as triple-negative breast cancer (TNBC) and bladder cancer:
Gene Regulation: Stabilizes oncogenic mRNAs (e.g., MYC, CCND1) and enhances transcription factors like STAT3 and nuclear EGFR .
Therapeutic Target: High NONO expression correlates with poor prognosis and chemoresistance in TNBC .
PRRSV Inhibition: In swine, NONO interacts with porcine reproductive and respiratory syndrome virus (PRRSV) N protein and IRF3, forming a complex that activates IFN-β signaling and suppresses viral replication .
Cross-Reactivity: Detects zebrafish and bovine NONO homologs despite being primarily validated in humans/mice .
The NONO antibody has enabled discoveries in virology and oncology, highlighting NONO’s dual role as a host defense modulator and oncogenic driver. Ongoing research explores its potential as a biomarker for antiviral therapies or cancer prognostics . Challenges include resolving its context-dependent roles—pro-viral in flaviviruses versus antiviral in PRRSV—and developing isoform-specific detection tools .